Douglas Tsao Boosts Rapport Therapeutics Price Target to $66 on Strong RAP-219 Differentiation and Robust Phase 2 Data
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Douglas Tsao raised Rapport Therapeutics' price target to $66 and maintained a Buy rating, citing strong Phase 2 data for RAP-219 and its mechanistic differentiation from existing therapies. Truist Financial also issued a Buy rating with a $56 price target on August 6.
H.C. Wainwright analyst Douglas Tsao has maintained their bullish stance on RAPP stock, giving a Buy rating on August 6.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Douglas Tsao has given his Buy rating due to a combination of factors that strengthen the investment case for Rapport Therapeutics. After an in-depth discussion with management, he increased his price target to $66, reflecting higher conviction in RAP-219’s commercial opportunity, supported by an enhanced sales multiple and clear mechanistic differentiation versus existing therapies.
Tsao emphasizes RAP-219’s selective action on TARP γ8, which is concentrated in brain regions relevant to focal-onset seizures and acute bipolar mania, helping avoid the motor side effects seen with broader AMPA inhibitors like perampanel. He also views the Phase 2 data as robust and internally consistent, with meaningful reductions in both clinically observed seizures and RNS-measured long episodes, alongside favorable tolerability, all of which underpin his positive outlook on the program and the company.
In another report released on August 6, Truist Financial also maintained a Buy rating on the stock with a $56.00 price target.